SNDX vs. SDGR, CPRX, GPCR, NAMS, RNA, HRMY, PTCT, AMRX, GLPG, and GERN
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Schrödinger (SDGR), Catalyst Pharmaceuticals (CPRX), Structure Therapeutics (GPCR), NewAmsterdam Pharma (NAMS), Avidity Biosciences (RNA), Harmony Biosciences (HRMY), PTC Therapeutics (PTCT), Amneal Pharmaceuticals (AMRX), Galapagos (GLPG), and Geron (GERN). These companies are all part of the "pharmaceutical preparations" industry.
Syndax Pharmaceuticals (NASDAQ:SNDX) and Schrödinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.
Syndax Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.
Syndax Pharmaceuticals received 317 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 64.48% of users gave Syndax Pharmaceuticals an outperform vote while only 54.12% of users gave Schrödinger an outperform vote.
Schrödinger has a net margin of 18.79% compared to Syndax Pharmaceuticals' net margin of 0.00%. Schrödinger's return on equity of -23.58% beat Syndax Pharmaceuticals' return on equity.
In the previous week, Schrödinger had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 4 mentions for Schrödinger and 2 mentions for Syndax Pharmaceuticals. Schrödinger's average media sentiment score of 0.89 beat Syndax Pharmaceuticals' score of -0.05 indicating that Schrödinger is being referred to more favorably in the news media.
Syndax Pharmaceuticals currently has a consensus target price of $34.42, suggesting a potential upside of 65.54%. Schrödinger has a consensus target price of $43.50, suggesting a potential upside of 80.95%. Given Schrödinger's higher probable upside, analysts clearly believe Schrödinger is more favorable than Syndax Pharmaceuticals.
Schrödinger has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Schrödinger, indicating that it is currently the more affordable of the two stocks.
79.1% of Schrödinger shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Schrödinger shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Schrödinger beats Syndax Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
